C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
bacterial pneumonia
efficacy
meropenem
meropenem concentration
therapeutic drug monitoring
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
14
03
2022
revised:
01
05
2022
accepted:
14
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled from the intensive care unit. Factors affecting the meropenem trough concentration were analyzed, and a multiple linear regression model was constructed. Logistic regression analyses were used to investigate the relationship between Ctrough and clinical efficacy. A total of 64 patients were enrolled, in whom 210 meropenem concentrations were measured. Of the total, 60.9% (39/64) were considered clinically successful after treatment. Ctrough may increase with increased blood urea nitrogen, albumin, and concomitant antifungal use. By contrast, concentration may decrease with increased endogenous creatinine clearance rate. Six variables, including Ctrough/minimum inhibitory concentration (MIC) > 4, were associated with the efficacy of meropenem. There was an independent correlation between Ctrough/MIC > 4 and efficacy after fully adjusting for confounding factors. Based upon renal function indexes, it is possible to predict changes in meropenem concentration and adjust the dosage precisely and individually. Ctrough/MIC > 4 is a potential instrument to predict successful treatment with meropenem.
Identifiants
pubmed: 35625314
pii: antibiotics11050670
doi: 10.3390/antibiotics11050670
pmc: PMC9137711
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Hunan Pharmaceutical Association of China
ID : HMA202001002
Références
Rev Port Cardiol (Engl Ed). 2018 Jan;37(1):25-33
pubmed: 29352692
J Antimicrob Chemother. 2018 Dec 1;73(12):3413-3422
pubmed: 30304491
J Antimicrob Chemother. 2002 Sep;50(3):425-8
pubmed: 12205070
Int J Antimicrob Agents. 2019 Dec;54(6):790-797
pubmed: 31284041
Med Sci (Paris). 2018 Oct;34 Focus issue F1:26-32
pubmed: 30403171
Respir Care. 2014 Apr;59(4):574-81
pubmed: 24106319
Drugs. 2018 Aug;78(12):1259-1270
pubmed: 30128699
J Pharm Sci. 2022 Jun;111(6):1833-1842
pubmed: 35090867
Med Clin North Am. 2019 May;103(3):487-501
pubmed: 30955516
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S120-5
pubmed: 20597661
Clin Microbiol Infect. 2006 Jun;12(6):501-3
pubmed: 16700696
Intensive Care Med. 2014 Mar;40(3):380-7
pubmed: 24356862
Lancet Infect Dis. 2014 Jun;14(6):498-509
pubmed: 24768475
Clin Pharmacokinet. 2020 Feb;59(2):173-205
pubmed: 31432468
Br J Clin Pharmacol. 2016 Jun;81(6):1113-23
pubmed: 26852277
Clin Infect Dis. 2017 Sep 15;65(6):1033-1036
pubmed: 28505263
Antimicrob Agents Chemother. 1994 May;38(5):931-6
pubmed: 8067772
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Drugs Aging. 2011 Nov 1;28(11):903-12
pubmed: 22054231
J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897
pubmed: 29091190
J Antimicrob Chemother. 2015 May;70(5):1495-502
pubmed: 25608584
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371
pubmed: 34430671
Crit Care. 2011;15(5):R206
pubmed: 21914174
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4577-84
pubmed: 27185798
J Antimicrob Chemother. 2022 May 29;77(6):1670-1675
pubmed: 35325155
PLoS One. 2013 Sep 19;8(9):e74937
pubmed: 24069367
Clin Chest Med. 2018 Dec;39(4):691-701
pubmed: 30390742
Intensive Care Med. 2020 Jun;46(6):1127-1153
pubmed: 32383061
Intensive Care Med. 2011 Apr;37(4):632-8
pubmed: 21136037
Int J Antimicrob Agents. 2010 Oct;36(4):332-9
pubmed: 20685085
J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):276-285
pubmed: 28943823
Eur Respir J. 2011 Jun;37(6):1332-9
pubmed: 20847075
J Antimicrob Chemother. 2015 Mar;70(3):882-90
pubmed: 25362574
J Antimicrob Chemother. 2010 Nov;65(11):2428-35
pubmed: 20817742
Am J Med. 2004 Nov 15;117(10):726-31
pubmed: 15541321
Drugs. 1995 Jul;50(1):73-101
pubmed: 7588092
Eur J Clin Pharmacol. 2017 Mar;73(3):333-342
pubmed: 27966034
Ther Drug Monit. 2016 Oct;38(5):593-9
pubmed: 27454665
J Clin Microbiol. 2021 Nov 18;59(12):e0021321
pubmed: 34550809
Microorganisms. 2021 Jul 14;9(7):
pubmed: 34361942
Int J Antimicrob Agents. 2019 Sep;54(3):309-317
pubmed: 31229669
Crit Care Clin. 2011 Jan;27(1):19-34
pubmed: 21144984
Eur J Clin Pharmacol. 2022 May;78(5):823-829
pubmed: 35171317
Pharmacotherapy. 2016 Dec;36(12):1229-1237
pubmed: 27862103
Nephron. 1976;16(1):31-41
pubmed: 1244564
Crit Care Med. 2015 Mar;43(3):527-33
pubmed: 25493971
Infect Drug Resist. 2022 Feb 11;15:439-453
pubmed: 35177911
Drugs R D. 2019 Jun;19(2):177-189
pubmed: 31090024
Antimicrob Agents Chemother. 2013 Feb;57(2):708-15
pubmed: 23147743
Infect Dis Ther. 2021 Mar;10(1):75-92
pubmed: 33492641
Chest. 2012 Jul;142(1):30-39
pubmed: 22194591
J Infect Public Health. 2021 Jan;14(1):131-138
pubmed: 33234410
Drugs Aging. 2017 Feb;34(2):115-121
pubmed: 28097633
Crit Care. 2018 Sep 24;22(1):233
pubmed: 30244674
Antimicrob Agents Chemother. 2007 May;51(5):1725-30
pubmed: 17307978
Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4300-3
pubmed: 26636517
Antimicrob Agents Chemother. 2015;59(6):2995-3001
pubmed: 25753628
Crit Care. 2017 Oct 21;21(1):263
pubmed: 29058601
Chest. 2010 Mar;137(3):552-7
pubmed: 19880910
Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850
pubmed: 33106863